{"name":"Compass Therapeutics","slug":"compass-therapeutics","ticker":"CMPX","exchange":"NASDAQ","domain":"compasstherapeutics.com","description":"Compass Therapeutics is a biopharmaceutical company focused on developing innovative therapies for immuno-oncology and bispecifics. The company has a pipeline of promising candidates, including Pembrolizumab (KEYTRUDA), CTX-8371, CTX-10726, and CTX-471. With a strong focus on research and development, Compass Therapeutics aims to bring life-changing treatments to patients with cancer. As a relatively new player in the market, the company is poised for growth and expansion in the coming years.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Thomas Schuetz","sector":"Immuno-Oncology / Bispecifics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$250M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":55969000,"netIncome":-66489000,"cash":30643000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Pembrolizumab (KEYTRUDA) patent cliff ($10.8B at risk)","drug":"Pembrolizumab (KEYTRUDA)","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"trial","headline":"Compass Therapeutics Announces Initiation of Phase 1 Clinical Trial for CTX-10726","summary":"Compass Therapeutics has initiated a Phase 1 clinical trial for CTX-10726, a novel bispecific antibody for the treatment of cancer.","drugName":"CTX-10726","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Compass Therapeutics Enters into Collaboration Agreement with Leading Cancer Research Institute","summary":"Compass Therapeutics has entered into a collaboration agreement with a leading cancer research institute to advance the development of its immuno-oncology pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxPTF9kWk8tNnZRZ0F0TGVjZ01CZGdKLTRhTDhQb2l0Qi1PXzl2U3R3ZlREZTFwMHZvWjB2ZFFuc0czVDZXdkcxa2Q4MEVYWG5kVjd4UmlVbk5Db0FweFBXUE1pcE4tYkpnWkNYQ2o0Q2NPa1loOTRETnpEdmJ3S1ZNdEJTS2pGMmlsWjh1WTd1TFNpVGtzZ1lHelA0VzZPOGo4eVJiUE4tN2pYMkJ0cUpwTGV2d19xS25EQWVONDZXWEhsMXBBUTlaWmxuNjlISTdlTWpTa0pkUnpOR0M1ZWRJUXpXQjBrdXE5X1lBeHB6SGFPUEFoRTNxVGRwN3YtRnV2eHA5V1lOWkcyTGhCM2l6ZV96eDZjTGRaaEtWYjZVZFdUS1FaY0Q4TVRiZUg2X19UajdEbmJ0WFBBbXk4Qm1STw?oc=5","date":"2026-04-01","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Co","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-07","type":"regulatory","source":"simplywall.st","summary":"A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance - simplywall.st","headline":"A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQVlRkTll3MTFwUmw2M25SeXdYSkxRd2JSZnhSQXhJSzhBb09RblViLVlJR2ZzbHktZnpLaEpRdkdITVBJOExRVkptR19tVmFHZ2p0YVlSeXlLa2o2cGxvYUFnTGpqZkFodlM0SUVFN3hqMUlyUncwWW9CNWt6NElmRHZScUN4cnBrLUNoMk1OajZRNG1uSFRKVmlBbmJSOG9TeF83VmstWWthV0NVMlhoUXpDbC1KeVBYMXgzeGJCd01Nb0xTVHJvQVVOZGxSY2xSMUozQnlBdTcxNHIxVGl4S2FLdzA5b3daM20zcmEyb1czVjhtbW1QOGVKY1QydEdBSzVDOFhYLVlQTkFMdUNyWFI0cmhSYmVOYkljNGZR?oc=5","date":"2026-03-02","type":"regulatory","source":"PR Newswire","summary":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (202","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQOUZWdXJCVTZXVU00QWtZYnBQdkd4cnlPSVByYTUzWUVvOU9mRjhHdWJKbVg1OVA0Mk1SRWRJQXJ2Qk9nbkFnRExXaVk5TFNrRGp4QS1DeEp0cGJYTWpvV1pobVhHd0g0SE5xcUNNM0g3ZUlmLWl5dkxzcFFoMEZGMHk0TzdSckI3cGJHOWRGbXBvNXVkUmtqREtxWmpBWk1RLVZNRHViczFXa0FtT0dCT1g4SGJ3bFctSTdGVmg2eDloWlczWjUtOTVB?oc=5","date":"2026-01-05","type":"pipeline","source":"GlobeNewswire","summary":"Compass Therapeutics Announces Key Leadership Appointments - GlobeNewswire","headline":"Compass Therapeutics Announces Key Leadership Appointments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPdzBmc1hNM3ZEZHdaSjBuZFE5R0p3QWlMek9MSHhIVVZ1NXRlc1FwTGJEWE9OODB2WnMyNlpTTkphOHVEZUFGYm53WmpoZXBtNFhNcFhRSG1MSDZCWjM3MnhVRUlQektwWk1WZENBNEpSYXRmNWNuaGQ4MDZneVpGdW5scklFdEVhc1JTYlpQYjBwcFdORHNCTmlYdHV4NERhSXc?oc=5","date":"2026-01-05","type":"pipeline","source":"Stock Titan","summary":"New leaders join Compass Therapeutics as it advances cancer drugs - Stock Titan","headline":"New leaders join Compass Therapeutics as it advances cancer drugs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-13","type":"pipeline","source":"simplywall.st","summary":"Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - simplywall.st","headline":"Compass Therapeutics And 2 Other Promising Penny Stocks To Consider","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOVEE2MG5tanBHNGE5M3lpVGliSTI1Tnc2R21RQXl2NjhUbnNJTi1zZHhnd1BZdEpKQ3VidTBoXzNXMFRWdVRrR2hlOUM2RDlFanVXNlI4QWFBZXpDWGtoV0xQY2x0RENmLVR0Q3BhdmV4UXN1ZEhZOEhhRzJ3cHpUWUlrUQ?oc=5","date":"2025-04-01","type":"deal","source":"StocksToTrade","summary":"CMPX Shares Plummet: Buying Opportunity? - StocksToTrade","headline":"CMPX Shares Plummet: Buying Opportunity?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE12ZnRSM3hEdWowejJkeVpnYVh1WTFkeHI4S1gtOGh0dnRtRTd3NDRZTnlIZnR6amtyamJWTG9zbThtM1VPMDlydlFpMlNBeGtx?oc=5","date":"2024-02-14","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQZ0g4MmRwWURSelkxbTRnNVZER0pwbDF1OHdxTDhjaXB3bnJLSjVYMlBGZG1ZbzRPeWgyeFZmZkxuOVVZdHRubFltckdlLWZfUjVSZFZqM2d3ejQ1WXdwbXRLbHNrcmpEODk4enl0WE1TT1VjVnlzOGljY2dXa0ktWQ?oc=5","date":"2022-05-17","type":"pipeline","source":"MarketBeat","summary":"Top Compass Therapeutics (CMPX) Competitors 2026 - MarketBeat","headline":"Top Compass Therapeutics (CMPX) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9hazIxalBESmRsbjZZcnRUNGxLTE84MzdaOUdYdzdobWF3RGJWVklCWElpOE9Bd0k4cXJJaHhQMHZTYTk4T3FfVmJHdWwxdmtSTXNPSU5hMnpRSzVq?oc=5","date":"2020-11-12","type":"pipeline","source":"TradingView","summary":"CMPX Stock Price and Chart — NASDAQ:CMPX - TradingView","headline":"CMPX Stock Price and Chart — NASDAQ:CMPX","sentiment":"neutral"}],"patents":[{"drugName":"Pembrolizumab (KEYTRUDA)","drugSlug":"pembrolizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10800000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Immuno-Oncology","Bispecifics"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":55969000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-66489000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":30643000,"cashHistory":[],"totalAssets":219588000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}